Estimation of Serum Creatinine, Aspartate Aminotransferase, Alanine Transaminase, and Hemoglobin A1c% Levels among Diabetic Patients using Metformin/Dipeptide Peptidase-4 Inhibitor Combination and Insulin – A Cross-Sectional Study
Abstract
BACKGROUND: Diabetes is a leading cause of morbidity and mortality worldwide, imposing a considerable burden on health systems and societies as it affects both individuals and their families and has a large impact on the economic and social development of a country. Nowadays, to treat diabetes, patients are taking drugs such as metformin in combination with dipeptide peptidase-4 (DPP-4) inhibitors and insulin for their treatment. There are many physiological and pathological changes while taking drugs for treating diabetes.AIM: Through this research, we can have an idea about the health of the patient and help to detect the level in which different drugs are affecting the patient’s kidney and liver.
METHODS: A cross-sectional study was done on diabetes type 1 and type 2 diabetic patients who are undergoing treatment with insulin and DPP-4 inhibitors/metformin combination drugs. The study continued for 3 months including preparation, practice, and data analysis.
RESULTS: In this study, our results show there is no significant change in all biochemical parameters: aspartate aminotransferase (AST), alanine transaminase, creatinine, and hemoglobin A1c (HbA1c) between diabetic patients treated with insulin and metformin/DPP-4 combination.
CONCLUSION: Metformin/DPP-4 combination gives a better glycemic control than other medications, whereas the levels of AST, creatinine, and HbA1c are unaffected using either insulin or metformin/DPP-4 inhibitors combination.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.